Mizuta, H., Okada, K., Araki, M., Adachi, J., Takemoto, A., Kutkowska, J., . . . Katayama, R. (2021). Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature Portfolio.
Chicago Style (17th ed.) CitationMizuta, Hayato, et al. Gilteritinib Overcomes Lorlatinib Resistance in ALK-rearranged Cancer. Nature Portfolio, 2021.
MLA (8th ed.) CitationMizuta, Hayato, et al. Gilteritinib Overcomes Lorlatinib Resistance in ALK-rearranged Cancer. Nature Portfolio, 2021.
Warning: These citations may not always be 100% accurate.